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Abstract: Alemtuzumab is a humanized chimeric monoclonal antibody targeting CD52. 
Although this agent already has an important role in the treatment of chronic lymphocytic leuke-
mia (CLL), many of its uses are still being deﬁ  ned. Early trials showed alemtuzumab’s value in 
refractory disease and helped to deﬁ  ne its excellent activity in the bone marrow, spleen and 17p 
deleted patients. The CAM307 trial has demonstrated alemtuzumab’s efﬁ  cacy as monotherapy 
in the front-line setting, and ultimately led to its FDA approval as frontline therapy. Especially 
promising is the trend toward improved response in patients with high risk cytogenic abnormali-
ties (17p del, 11q del, trisomy 12). The various consolidation trials have also provided promising 
results of achieving eradication of minimal residual disease (MRD). Although the ultimate beneﬁ  t 
of achieving MRD negativity remains under investigation, alemtuzumab’s potent activity on 
the bone marrow will likely make it an important part of combination therapy.
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Introduction
Alemtuzumab is a humanized chimeric monoclonal antibody targeting CD52. Although 
this agent already has an important role in the treatment of chronic lymphocytic leu-
kemia (CLL), many of its uses are still being deﬁ  ned. Most experience using alemtu-
zumab has been in the relapsed and refractory setting. Its initial FDA approval in CLL 
was based on a pivotal trial of 93 ﬂ  udarabine-refractory patients (Keating et al 2002). 
Alemtuzumab’s particularly good activity in high risk patients at clearing peripheral 
blood, bone marrow and spleen of CLL cells have led to its consideration in the ﬁ  rst-
line setting. The impressive results of a recent study, the CAM307 trial, have led to 
alemtuzumab’s approval for up-front use in CLL. Despite its approval in both upfront 
and relapsed settings, alemtuzumab’s role in CLL treatment continues to evolve.
The case for alemtuzumab in the up-front setting
Ample evidence of alemtuzumab’s efﬁ  cacy in difﬁ  cult patient populations and in 
speciﬁ  c disease scenarios have ultimately led to its examination in the front-line set-
ting. In 1997, Osterborg et al (1997) published the results of a European, multi-center 
trial in 1997 using single-agent alemtuzumab in 29 CLL patients who had relapsed 
after ﬁ  rst-line treatment or who had refractory disease. The overall response rate 
was 41% and complete response was 4%. Its efﬁ  cacy at clearing CLL cells from 
the peripheral blood (97% of patients) and from the bone marrow (36% of patients) 
was particularly notable. In addition, splenomegaly completely resolved in 32% of 
patients. On the other hand, lymph nodes were reduced to normal in only 2%. Rai 
et al (2002a) published a study in which 24 ﬂ  udarabine-refractory patients received 
single-agent alemtuzumab and obtained a response-rate of 33% (there were no com-
plete responses). Also in 2002, Keating et al (2002) published data from the CAM211 
trial in which 93 ﬂ  udarabine-refractory patients received alemtuzumab and achieved 
a 33% overall response rate.Therapeutics and Clinical Risk Management 2008:4(2) 460
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Further evidence to help deﬁ  ne alemtuzumab’s role in 
high risk patients was shown in a study by Stilgenbauer 
et al (2002) in 2002. A response rate of 54% was achieved 
in ﬂ  udarabine-refractory patients with the unfavorable muta-
tion 17p deletions or p53 abnormalities. A subsequent trial 
performed by Lozanski et al (2004) found a 31% response 
in patients with this high-risk proﬁ  le.
Alemtuzumab’s use in combination with other agents 
also showed impressive results in refractory disease. The 
combination of alemtuzumab and ﬂ  udarabine was examined 
in trials published by Kennedy et al (2002) (n = 6) and Elter 
et al 2005) (n = 36). Both studies found an overall response 
rate of 83%. Faderl et al (2003) used alemtuzumab in com-
bination with rituximab in this population and achieved a 
response rate of 63%. This history of success in these proﬁ  les 
of high-risk populations, particularly with p53 deletions, 
extensive marrow disease with high peripheral lymphocyte 
counts, and without bulky lymph nodes, led investigators to 
examine roles for alemtuzumab in the up-front setting.
Alemtuzumab monotherapy 
in the ﬁ  rst-line setting
Use of alemtuzumab as monotherapy in CLL in the ﬁ  rst-line 
setting was ﬁ  rst reported by Osterborg et al (1996) in a pilot 
study of 9 patients (Table 1). Five received intravenous and 
4 received subcutaneous alemtuzumab at a dose of 30 mg 3 
times/week for a maximum of 18 weeks. Five patients achieved 
a partial remission and 3 achieved a complete remission. 
Duration of response ranged from 8 to 24 months. A phase II 
study was published in 2002 (Lundin et al 2002). Single-agent 
alemtuzumab was administered subcutaneously thrice weekly 
for 18 weeks to 41 patients as ﬁ  rst-line treatment. Thirty-eight 
patients responded to therapy, for an overall response rate of 
87 % ( 95% CI, 76%–98%) – 19% achieved a complete remis-
sion and 68% achieved a partial remission. 95% of patients 
cleared CLL cells in their peripheral blood at a median of 21 
days of treatment, and 66% achieved CR or nodular PR in the 
bone marrow after the full course of 18 weeks of treatment. 
The treatment was generally well-tolerated with neutropenia 
(21%) and cytomegalovirus (CMV) reactivation (10%) being 
the most serious toxicities. There were transient injection-site 
skin reactions in 90% of patients.
The CAM307 trial
Results of an international prospective, randomized, con-
trolled trial comparing alemtuzumab to chlorambucil as 
front-line therapy was reported at the American Society of 
Hematology annual meeting in 2006 (Hillmen et al 2006) and 
published in December 2007 (Hillmen et al 2007). A total of 
297 patients were accrued, and were randomized to receive 
either alemtuzumab (n = 149) 30 mg IV thrice weekly for up 
to 12 weeks or chlorambucil (n = 147) 40 mg/m² PO every 
28 days for a maximum of 12 cycles. The primary endpoint 
was progression-free survival (PFS) and secondary endpoints 
were response rate, overall survival, and safety.
The alemtuzumab arm showed an overall response rate 
of 83% compared to a 55% response rate in the chlorambu-
cil arm. Complete responses were seen in 24% and of the 
alemtuzumab arm and 2% of the chlorambucil arm. MRD 
negativity was achieved in 11 of 36 complete responders 
in the alemtuzumab arm vs none in the chlorambucil arm. 
Time to alternative treatment was 23.3 months for the 
alemtuzumab arm vs 14.7 months for the chlorambucil arm 
(p = 0.0001).
Table 1 Alemtuzumab monotherapy trial in front-line setting
Study Patients Regimen Response rate Complete response Median progression-
free survival
Osterberg et al (1996) 
single arm pilot study
n = 9 Alemtuzumab 30 mg 
TIW for 18 weeks (4 
patients received SQ; 
5 patients received IV)
89% (n = 8) 33% (n = 3)
Lundin et al (2002) 
phase II single arm 
study
n = 41 Alemtuzumab 30 mg 
TIW for 18 weeks SQ
87% (n = 38) 19% (n = 7)
Hillmen et al (2006) n = 297 for entire 
trial; n = 149 for 
alemtuzumab arm
Alemtuzumab 30 mg 
TIW for 12 weeks
Alemtuzumab arm 
83% (n = 124)
Alemtuzumab arm 
24% (n = 36)
Alemtuzumab 
arm = 21.7 months
CAM307 Phase III 
study of alemtuzumab 
vs chlorambucil
n = 148 chlorambucil 
arm
Chlorambucil 
40 mg/m2 PO q28 days 
for max 12 cycles
Chlorambucil arm 
55% (n = 82)
Chlorambucil arm 
2% (n = 3)
Chlorambucil 
arm = 12.5 monthsTherapeutics and Clinical Risk Management 2008:4(2) 461
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Especially notable was that these beneﬁ  ts were particularly 
evident in patients with high-risk cytogenetic abnormali-
ties. Of the 282 patients who had cytogenetic analysis, 231 
patients (82%) revealed abnormalities, including 19% with 
11q deletions, 7% with 17p deletions and 14% with trisomy 
12 (Robak et al 2006). Patients with 17p deletions who were 
treated with alemtuzumab had a PFS of 10.7 months compared 
to 2.2 months for patients who received chlorambucil. Over-
all response rates for these two groups were 64% and 20%, 
respectively. Patients with 11q deletions had response rates 
of 87% and 29% in the alemtuzumab and chlorambucil arms, 
respectively. PFS was 8.5 months in both arms. Similarly, 
patients with trisomy 12 had a PFS of 18.3 months vs 12.9 on 
the alemtuzumab and chlorambucil arms, respectively. These 
two groups had similar response rates of 83% in the alemtu-
zumab arm and 80% in the chlorambucil arm. Of particular 
note, however, is that although these beneﬁ  ts for patients 
with high risk cytogenetics were statistically signiﬁ  cant in 
terms of response, this did not extend to PFS. Although there 
was a trend of increased PFS in the 17p group treated with 
alemtuzumab, it did reach statistical signiﬁ  cance.
In terms of toxicities, the incidence of grade 3 and 4 neu-
tropenia occurred in 45% of the alemtuzumab arm vs 26% of 
the chlorambucil arm. Infectious complications were reported 
in 76% of patients on the alemtuzumab arm compared to 50% 
on the chlorambucil arm. CMV viremia occurred in 52% of 
patients on the alemtuzumab arm and 16% had symptomatic 
CMV infections. Only 7.5% of patients on the chlorambucil 
had evidence of CMV viremia by PCR, none of whom were 
symptomatic.
Although this trial adds important data in terms of the use 
and activity of alemtuzumab as single-agent in the front line, 
the results must be cautiously interpreted due to its relatively 
short median follow-up of only 24.6 months, and the fact that 
84% of patients in each arm remain alive. Nevertheless, the 
trial adds particularly useful data in terms of approach to 17p 
deleted patients, and may ultimately contribute to the creation 
of a new standard of care for these patients.
Table 2 Alemtuzumab consolidation trials
Study Patients Regimen Response rate MRD negativity Median progression-
free survival/
survival
O’Brien et al (2003) 
Alemtuzumab con-
solidation with 10 mg 
vs 30 mg doses
n = 41 Alemtuzumab given 
after ﬂ  udarabine induc-
tion in the following 
doses: 10 mg IV TIW 
for 4 weeks (n = 24); 
or 30 mg IV TIW for 
4 weeks (n = 34)
Improved response after 
induction all patients = 46% 
(n = 19): 30 mg arm = 56% 
10 mg arm = 39%
38% (11 of the 29 
patients tested for 
MRD)
Not reached at median 
follow of 18 months
Wendtner et al (2003) 
phase III trial of alemtu-
zumab vs observation 
following ﬂ  udarbine-
based therapy
n = 21 Alemtuzumab 30 mg 
SQ TIW consolidation vs 
observation following a 
response to ﬂ  udarabine-
based therapy
(18%) 2 of 11 on alemtu-
zumab arm had improved 
response over induction
83% (5 of 6 patients 
tested for MRD in 
peripheral blood)
Alemtuzumab arm: not 
reached at median fol-
low up of 21.4 months.
Observation arm: 
24.7 months
Moreton et al (2005) 
Treatment of ﬂ  udarabine-
refractory patients to 
best possible remission
n = 91 Alemtuzumab 30 mg 
TIW (SQ or IV) until 
maximum response 
(median 9 weeks)
53% (n = 49) overall 
response rate. 36% 
(n = 32) had CRs
20% (n = 18) Overall survival for 
MRD– patients not 
reached. Overall 
survival for MRD+ 
patients with CRs had 
a median survival of 
41 months.
CALGB (2003) Alem-
tuzumab following 
ﬂ  udarabine in previously 
untreated patients
n = 24 Alemtuzumab 30 mg 
SC for 6 weeks follow-
ing ﬂ  udarabine
66% overall response 
(12 of 18 patients who 
received alemtuzumab); 
22% CR; 44% PR
Montillo et al (2004) 
phase II study of alemtu-
zumab following clinical 
response to ﬂ  udarabine
n = 34 Alemtuzumab 10 mg 
SC for 6 weeks following 
response to ﬂ  udarabine
53% (18 of 34) patients 
had improved response 
over induction
56% (n = 19)
Abbreviations: CR, complete response; MRD, minimal residual disease; PR, partial response.Therapeutics and Clinical Risk Management 2008:4(2) 462
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Alemtuzumab consolidation
Although alemtuzumab has been shown to be less effective 
treating bulky lymph nodes, multiple studies have demon-
strated its utility in clearing the blood and bone marrow of 
disease (Dyer et al 1997; O’Brien et al 2003). Based on these 
observations, alemtuzumab has been used in several trials as 
consolidation therapy to eradicate minimal residual disease 
(MRD) in the bone marrow after initial therapy with other 
agents to debulk peripheral lymph nodes (Table 2).
In 1997 Dyer et al (1997) published a small study of 
6 CLL patients who were treated with ﬂ  udarabine, had 
persistent disease in the bone marrow, and then were 
treated with alemtuzumab. Five of the 6 patients achieved a 
hematologic and histological complete remission following 
alemtuzumab. O’Brien et al (2003) further examined the 
concept of eradication of MRD in a series of 41 patients. 
Forty-six per cent of the patients overall, and 56% of those 
patients that received the 30 mg dose (n = 17) had improve-
ment in their disease-response after the alemtuzumab 
treatment. Eleven (38%) of the 29 patients whose bone 
marrow was tested by two-color ﬂ  ow cytometry achieved 
a ﬂ  ow-negative remission. At a median follow-up of 18 
months, 6 patients remained disease-free (24–48 months 
after therapy) and median time to disease progression had 
not yet been reached at the time of their report or until 18 
months median follow-up. Fifteen patients (37%) were 
reported to have infectious complications, 9 of which were 
CMV reactivations.
At the annual meeting of the American Society of 
Clinical Oncology in 2005, Wendtner et al (2004) and the 
German CLL Study Group presented the results of a trial 
that randomized patients who responded to ﬂ  udarabine/
cyclophosphamide or ﬂ  udarabine alone to either alemtu-
zumab 30 mg subcutaneous 3 times per week for 12 weeks 
or observation. The trial was ultimately stopped early due 
to severe infectious toxicities. Of the 21 evaluable patients, 
11 were randomized to receive alemtuzumab. Patients in 
the alemtuzumab arm showed a signiﬁ  cantly longer PFS 
compared to those in the observation arm (no progression at 
a median of 21.4 months follow up vs 24.7 months). Seven 
of the 11 patients on the alemtuzumab arm had infectious 
complications including one life-threatening case of pulmo-
nary aspergillosis, 4 patients with CMV reactivation (2 with 
clinically evident CMV pneumonia), 1 tuberculosis and 1 
herpes zoster infection.
Moreton et al (2005) published a larger study in 2005 
using alemtuzumab in consolidation. Although these 
patients were previously treated, consolidation proved to 
be an attractive concept in the front-line setting as well. 
Ninety-one patients received alemtuzumab for a median of 
9 weeks. Thirty-six per cent obtained a complete remis-
sion, including 20 % (n = 18) who had obtained MRD 
negativity by ﬂ  ow cytometry. Of note, the patients who 
achieved MRD negativity had a signiﬁ  cantly prolonged 
treatment-free survival compared with patients with MRD 
positivity but with a clinical complete response (CR) 
(median treatment-free survival not reached vs 20 months, 
respectively (p   0.0001). MRD negative patients had not 
reached median overall survival vs median overall survival 
of 60 months for those patients that obtained CR but not 
MRD negativity. This study helped to initiate discussion 
as to whether or not MRD negativity should be a new goal 
of treatment (Montserrat 2005). It remains unclear as to 
whether achievement of MRD-negativity itself results in a 
better outcome, or if the ability to clear the bone marrow 
simply represents a group of patients with more sensitive 
disease. The issue is still being debated.
The Cancer and Leukemia Group B (CALGB) conducted 
a study using alemtuzumab following ﬂ  udarabine in the ﬁ  rst-
line (Rai et al 2002b, 2003). Fifty-six patients were enrolled 
and received 4 monthly cycles of single-agent ﬂ  udarabine. 
Patients that achieved stable disease or better after 2 months 
of observation following ﬂ  udarabine received alemtuzumab 
30 mg intravenously TIW for 6 weeks, intravenously. 
Another 24 patients underwent the same ﬂ  udarabine regimen, 
but received alemtuzumab subcutaneously if a response was 
achieved. In the ﬁ  rst group (designated to receive intravenous 
alemtuzumab), 36 of the 56 patients ultimately received alem-
tuzumab IV. Fifteen of those 36 improved to CRs (42%) and 
18 had PRs (50%) for an overall improvement of response 
rate to 92%. Of the 24 patients in the second (subcutaneous 
alemtuzumab) group, 18 patients qualiﬁ  ed to get subcutane-
ous alemtuzumab. Of those 18 patients, 12 (66%) improved 
their response, including 22% who achieved CRs and 44% 
who achieved PRs.
Mantillo et al also examined the achievement of MRD 
negativity following alemtuzumab consolidation in a phase 
II study of 34 patients (Montillo et al 2006). Patients who 
had a clinical response to ﬂ  udarabine-based therapy in the 
front-line received alemtuzumab 10 mg subcutaneously TIW 
for 6 weeks. Patients went on to have stem cell mobilization 
for transplant. Following treatment with the alemtuzumab, 
the CR rate improved from 35% after the ﬂ  udarabine treat-
ment to 79%. Nineteen patients (56%) achieved MRD 
negativity. There was CMV reactivation in 18 patients, all 
of whom were successfully treated with antiviral therapy. Therapeutics and Clinical Risk Management 2008:4(2) 463
Alemtuzumab in the up-front setting
Twenty-four of these patients underwent successful stem 
cell collection and 18 underwent autologous bone marrow 
transplant.
Infectious toxicities
of alemtuzumab
Alemtuzumab has well-known infectious complications. 
As described in the pivotal trials above, major infectious 
complications were observed in approximately half of 
the patients (Keating et al 2002; Rai et al 2002a). These 
infections included septicemia, opportunistic infections 
such as aspergillosis, Pneumocystis carinii, herpes simplex 
(re)activations, and cytomegalovirus. Generally, these infec-
tious complications have been found to be more common in 
patients who are not responding to alemtuzumab thereapy 
(Rai et al 2002a; Montillo et al 2006). In one study, Rai et al 
found major infections in only 2 of 8 responders, compared 
with 8 of 16 nonresponders. A retrospective evaluation 
of 27 patients treated for lymphoid malignancies at Dana 
Farber/Brigham and Women’s Hospital found that 56% 
(15 of 27) experienced opportunistic infections (including 
CMV(44%), progressive multifocal leukoencephalopathy, 
adenovirus, toxoplasmosis, and acanthamaebiasis). In 
addition, 30% nonopportunistic infections were found in 
22 patients (Martin et al 2006). These complications are 
particularly common when alemtuzumab is combined with 
purine analogs (Keating et al 2002).
Cytomegalovirus (CMV) infection is the most com-
mon complication. In the CAM307 trial, 52.4% of patients 
receiving alemtuzumab have asymptomatic positive CMV 
by PCR vs 7.5% of the patients who received chlorambucil. 
An additional 15.6% of patients on the alemtuzumab arm had 
symptomatic CMV involvement (Hillmen et al 2007).
Close monitoring of CMV copies by PCR during treat-
ment with alemtuzumab allows for detection of asymptomatic 
reactivation. There should be high suspicion of CMV infec-
tion in any patient with unexplained fever, increase in LFTs 
or respiratory symptoms, even with no detectable CMV in 
the blood. Typically, if CMV is detected, or if there is a high 
suspicion on infection, alemtuzumab is temporarily held 
and antiviral therapy is initiated. Some debate does exist 
as to what point alemtuzumab should be held and restarted. 
Published guidelines by O’Brien et al (2006) suggest that 
alemtuzumab be held only in the setting of severe infection 
or persistent symptoms.
Once signs and symptoms of infection have resolved, 
the therapy should be restarted. Both symptomatic and 
asymptomatic CMV in these patients usually responds to 
gancyclovir. Prophylaxis for prevention of varicella zoster 
and herpes simplex reactivation, as well as for pneumocystis 
carinii pneumonia, should also be given throughout treatment. 
These prophylactic antibiotics and CMV monitoring should 
be continued following alemtuzumab for approximately 6–8 
months, and at least until recovery of CD4+ T-cells.
Conclusion
Alemtuzumab’s role continues to expand. Early trials showed 
alemtuzumab’s value in refractory disease and helped to 
deﬁ  ne its excellent activity in the bone marrow, spleen and 
17p deleted patients. With this data, additional trials were 
developed in an attempt to further expand its role. The 
CAM307 trial has demonstrated alemtuzumab’s efﬁ  cacy as 
monotherapy in the front-line setting. Especially promising 
is the trend toward improved response in patients with high 
risk cytogenic abnormalities (particularly 17p del). This trend 
requires further investigation but notwithstanding, alemtu-
zumab is a reasonable ﬁ  rst-line choice for this population. 
The various consolidation trials have also provided promising 
results of achieving eradication of minimal residual disease 
(MRD). Although the ultimate beneﬁ  t of achieving MRD 
negativity remains under investigation, alemtuzumab’s 
potent activity on the bone marrow will likely make it an 
important part of combination therapy.
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